Optimizing the Use of Novel Therapies for Patients with Diffuse Large B-Cell Lymphoma

Each 1-hour session will include 3 topic modules focused on optimizing the use of novel therapies for patients with diffuse large B-cell lymphoma (DLBCL). Each event will employ an identical format that will include the following elements:

• Discussion of Steering Committee Members’ Treatment Recommendations
• Review of Available Clinical Research Findings
• Integration of Interactive Audience Q&A Discussion

MODULE 1 — Selection of First-Line Therapy for Patients with DLBCL

• Key factors guiding the selection of initial therapy for patients with DLBCL
• Extended follow-up from the Phase III POLARIX trial comparing polatuzumab vedotin/R-CHP to R-CHOP for previously untreated DLBCL; clinical activity observed with polatuzumab vedotin/R-CHP in various patient subsets
• Tolerability profile of polatuzumab vedotin/R-CHP versus R-CHOP in POLARIX
• Appropriate selection of candidates to receive polatuzumab vedotin as a component of up-front therapy for DLBCL
• Biological rationale for and emerging clinical trial data with tafasitamab and lenalidomide combination therapy, including from the Phase III frontMIND study
• Biological rationale for and published clinical trial data with Bruton tyrosine kinase inhibitors for patients with newly diagnosed DLBCL
• Design, eligibility criteria and primary and secondary endpoints of the Phase III ESCALADE trial of acalabrutinib in combination with R-CHOP for patients age 65 or younger with untreated non-GCB DLBCL
• Estimated completion date of ESCALADE and potential clinical role of acalabrutinib in treatment for DLBCL

MODULE 2 — Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL

• Factors affecting the selection and sequencing of therapies for patients with R/R DLBCL
• Key efficacy and safety findings with tafasitamab/lenalidomide for patients with R/R DLBCL; optimal application in routine practice
• Ongoing confirmatory Phase III firmMIND trial of tafasitamab/lenalidomide for patients with R/R DLBCL; estimated completion date
• Efficacy and safety outcomes with the approved bispecific antibodies glofitamab and epcoritamab in R/R DLBCL
• Optimal sequencing and practical implementation of glofitamab and epcoritamab for patients with R/R DLBCL
• Published research findings with and ongoing studies of bispecific antibodies in combination with other anticancer therapies and/or in earlier settings for DLBCL
• Mechanism of action of the novel CD19 x CD3 bispecific T-cell engager AZD0486; similarities and differences with available bispecific antibodies employed in non-Hodgkin lymphoma
• Antitumor activity documented with and ongoing evaluation of AZD0486 in patients with R/R follicular lymphoma and DLBCL

MODULE 3 — Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL

• Published research findings with polatuzumab vedotin in combination with bendamustine/rituximab for patients with R/R DLBCL
• Data from the Phase III SUNMO study design evaluating mosunetuzumab in combination with polatuzumab vedotin for R/R non-Hodgkin lymphoma
• Available efficacy and tolerability data with loncastuximab tesirine for R/R DLBCL
• Optimal sequencing of loncastuximab tesirine for individual patients and ongoing studies seeking to further define its role in treatment
• Scientific rationale for targeting CD30 in patients with DLBCL; mechanism of antitumor activity and structural components of the anti-CD30 ADC brentuximab vedotin (BV)
• Design and entry criteria of the Phase III ECHELON-3 trial evaluating BV in combination with rituximab/lenalidomide (R²) for patients with R/R DLBCL ineligible to receive autologous stem cell transplant or chimeric antigen receptor T-cell therapy
• Published efficacy and safety findings with the addition of BV to R² in ECHELON-3; FDA approval of BV and R² for R/R DLBCL; current role of this regimen in clinical practice

Each session will conclude with a 5-minute Q&A segment

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma (DLBCL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess which clinical and biological factors (eg, age, cell of origin, comorbidities) should influence the selection of first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), and use this insight to personalize treatment recommendations.
• Review the biological rationale for, available research findings with and ongoing investigation of Bruton tyrosine kinase inhibitors as a component of initial therapy for patients with DLBCL.
• Apply available clinical research findings in the formation of evidence-based therapeutic approaches for relapsed/refractory (R/R) DLBCL in patients who are unfit for intensive treatment.
• Evaluate the mechanisms of action of and available clinical trial findings with CD19-directed monoclonal antibodies and antibody-drug conjugates approved for use in R/R DLBCL.
• Appraise available research findings with and the current clinical role of CD30-targeted antibody-drug conjugate-based therapy for patients with R/R DLBCL.
• Consider published research data with and the current clinical role of bispecific antibodies targeting CD20 x CD3 for R/R DLBCL.
• Recognize the scientific justification for and potential clinical role of CD19 x CD3 bispecific antibodies for patients with DLBCL and other lymphoma subtypes.
• Discern the side effects and toxicities associated with available therapies for patients with DLBCL, and identify strategies to manage and mitigate them.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.  

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

Steering Committee — The following faculty reported relevant financial relationships with ineligible entities:

Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc. Dr Kamdar — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group. Dr LaCasce — Advisory Committees: Caribou Biosciences Inc, Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Pierre Fabre, Takeda Pharmaceuticals USA Inc. Dr Lunning — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Kite, A Gilead Company, Lyell Immunopharma, Pfizer Inc, Recordati. Dr Matasar — Advisory Committees and Consulting Agreements: AbbVie Inc, Allogene Therapeutics, Arvinas, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Visionary Pharmaceuticals; Contracted Research: Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Johnson & Johnson, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc; Expert Testimony: Recursion; Stock Options/Stock — Public Companies: Merck; Nonrelevant Financial Relationships: Arnold & Porter Kaye Scholer LLP. Dr Phillips — Advisory Boards/Consulting: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Caribou Biosciences Inc, Celgene Corporation, Genentech, a member of the Roche Group, Genetics Pharmaceuticals, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Johnson & Johnson, Kite, A Gilead Company, Lilly, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Xencor; Advisory Committees: BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Sobi; Data and Safety Monitoring Boards/Committees: Xencor; Nonrelevant Financial Relationships: Blood Cancer United. Prof Salles — Advisory Committees: AbbVie Inc, BeOne, Bristol Myers Squibb, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Novartis, Nurix Therapeutics Inc, Pfizer Inc, SERB Pharmaceuticals; Consulting Agreements: AbbVie Inc, Canopy Life Sciences, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Kite, A Gilead Company, ModeX Therapeutics, Treeline Biosciences; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc. Dr Westin — Advisory Committees: Genentech, a member of the Roche Group, Kite, A Gilead Company, Novartis; Consulting Agreements: AbbVie Inc, ADC Therapeutics, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research: ADC Therapeutics, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Regeneron Pharmaceuticals Inc.

Program Chair — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pfizer Inc.